Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Gut feeling: new supplement aims to soothe digestion and boost mood

NCT ID NCT06834984

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 11, 2026 · Updated 2 times

Summary

This study is testing whether a daily dietary supplement called Synbiotic+, which contains probiotics, prebiotics, and postbiotics, can improve gastrointestinal symptoms like bloating and irregular bowel movements in healthy women aged 25-65. Researchers will also look at markers of gut inflammation, immune health, and mood. The 60 participants will take either the supplement or a placebo for several weeks, and their gut health will be tracked through stool samples, diaries, and questionnaires.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a dietary supplement containing probiotics (Lactobacillus rhamnosus LGG and Bifidobacterium animalis subsp. lactis BB-12), a prebiotic (bacteriophages), and a postbiotic (tributyrin)
What this could lead to
If it works, this could point toward a simple daily supplement to reduce bloating, gas, and other common gut issues while also supporting mood and immune health.
What could go wrong
This is a small, early-stage study with only 60 healthy women, so results may not apply to everyone. The supplement is not a treatment for any disease, and benefits may be modest or no better than placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

103 people

The number who actually took part.

Started

May 2025

Finished

Sep 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

25 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Healthy adult women (age 25-65, with target average age of 50). * BMI \<30. * with moderate gastrointestinal symptoms. * Participants should be willing to follow the study protocol and attend clinic visits. Exclusion Criteria: * less than 25 years of age or greater than 65 years of age. * have a BMI \>30. * taken antibiotics within two months or any probiotic supplements within the past 14 days prior to the start of treatment. * current medications and dietary supplements will be assessed on a case-by- case basis and will result in exclusion if there is the possibility that the drugs or supplements used would influence the endpoints of the study. This would include statins, metformin, NSAIDs, MAO inhibitors, and hormone therapies. * Individuals with current disease diagnosis, including diagnosis of cancer, liver or kidney disease, gastrointestinal diseases, and cardiometabolic disorders (cardiovascular disease, diabetes, etc.) * pregnant and breastfeeding people. * overuse of alcohol as determined on a case-by-case self-reported alcohol use. * if the individual feels they are unable to adhere to the study requirements, which includes consuming capsules, providing stool or blood samples, tracking bowel movements and symptoms, and attending scheduled clinic visits.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal disease symptoms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Colorado State University Food and Nutrition Clinical Research Laboratory

    Fort Collins, Colorado, 80523, United States